You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 253 No. 8, February 22, 1985 TABLE OF CONTENTS
  JAMA
  •  Online Features
  PRELIMINARY COMMUNICATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Benefits of Danazol Treatment in Patients With Hemophilia A (Classic Hemophilia)

Harvey R. Gralnick, MD; Pascal Maisonneuve, MD; Yvette Sultan, MD; Margaret E. Rick, MD

JAMA. 1985;253(8):1151-1153.


Abstract

Danazol, an attenuated androgen, was given intermittently to three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.

(JAMA 1985;253:1151-1153)



Author Affiliations

From the Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md (Drs Gralnick and Rick); and Laboratoire d'Hemostase, Hospital Cochin, Paris (Drs Maisonneuve and Sultan).


Footnotes

Reprint requests to Chief, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bldg 10, Room 2C390, Bethesda, MD 20205 (Dr Gralnick).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Prophylactic Treatment of Hemophilia B Leyden with Anabolic Steroids
BRIET et al.
ANN INTERN MED 1985;103:225-226.
ABSTRACT  

Danazol and Hemophilia
Hathaway
JAMA 1985;253:1167-1167.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.